MKI67 and breast carcinoma: These findings, together with our observation of the prognostic value of KI67 in both node-negative and node-positive ER-positive patients, support the decision by the St Gallen International Expert Consensus to endorse KI67 for treatment decision-making in ER-positive early (1–3 axillary nodes) breast cancer patients [1].